Cholangiocyte senescence has been linked to primary sclerosing cholangitis (PSC). Persistent secretion of growth factors by senescent cholangiocytes leads to the activation of stromal fibroblasts (ASFs), which are drivers of fibrosis. The activated phenotype of ASFs is characterized by an increased sensitivity to apoptotic stimuli. Here, we examined the mechanisms of apoptotic priming in ASFs and explored a combined targeting strategy to deplete senescent cholangiocytes and ASFs from fibrotic tissue to ameliorate liver fibrosis. Using a coculture system, we determined that senescent cholangiocytes promoted quiescent mesenchymal cell activation in a platelet-derived growth factor (PDGF)-dependent manner. We also identified B-cell lymphoma-extra large (Bcl-xL) as a key survival factor in PDGF-activated human and mouse fibroblasts. Bcl-xL was also up-regulated in senescent cholangiocytes. In vitro, inhibition of Bcl-xL by the small molecule Bcl-2 homology domain 3 mimetic, A-1331852, or Bcl-xL-specific small interfering RNA induced apoptosis in PDGF-activated fibroblasts, but not in quiescent fibroblasts. Likewise, inhibition of Bcl-xL reduced the survival and increased apoptosis of senescent cholangiocytes, compared to nonsenescent cells. Treatment of multidrug resistance 2 gene knockout (Mdr2-/- ) mice with A-1331852 resulted in an 80% decrease in senescent cholangiocytes, a reduction of fibrosis-inducing growth factors and cytokines, decrease of α-smooth muscle actin-positive ASFs, and finally in a significant reduction of liver fibrosis. CONCLUSION: Bcl-xL is a key survival factor in ASFs as well as in senescent cholangiocytes. Treatment with the Bcl-xL-specific inhibitor, A-1331852, reduces liver fibrosis, possibly by a dual effect on activated fibroblasts and senescent cholangiocytes. This mechanism represents an attractive therapeutic strategy in biliary fibrosis. (Hepatology 2018;67:247-259).
Cholangiocyte senescence has been linked to primary sclerosing cholangitis (PSC). Persistent secretion of growth factors by senescent cholangiocytes leads to the activation of stromal fibroblasts (ASFs), which are drivers of fibrosis. The activated phenotype of ASFs is characterized by an increased sensitivity to apoptotic stimuli. Here, we examined the mechanisms of apoptotic priming in ASFs and explored a combined targeting strategy to deplete senescent cholangiocytes and ASFs from fibrotic tissue to ameliorate liver fibrosis. Using a coculture system, we determined that senescent cholangiocytes promoted quiescent mesenchymal cell activation in a platelet-derived growth factor (PDGF)-dependent manner. We also identified B-cell lymphoma-extra large (Bcl-xL) as a key survival factor in PDGF-activated human and mouse fibroblasts. Bcl-xL was also up-regulated in senescent cholangiocytes. In vitro, inhibition of Bcl-xL by the small molecule Bcl-2 homology domain 3 mimetic, A-1331852, or Bcl-xL-specific small interfering RNA induced apoptosis in PDGF-activated fibroblasts, but not in quiescent fibroblasts. Likewise, inhibition of Bcl-xL reduced the survival and increased apoptosis of senescent cholangiocytes, compared to nonsenescent cells. Treatment of multidrug resistance 2 gene knockout (Mdr2-/- ) mice with A-1331852 resulted in an 80% decrease in senescent cholangiocytes, a reduction of fibrosis-inducing growth factors and cytokines, decrease of α-smooth muscle actin-positive ASFs, and finally in a significant reduction of liver fibrosis. CONCLUSION:Bcl-xL is a key survival factor in ASFs as well as in senescent cholangiocytes. Treatment with the Bcl-xL-specific inhibitor, A-1331852, reduces liver fibrosis, possibly by a dual effect on activated fibroblasts and senescent cholangiocytes. This mechanism represents an attractive therapeutic strategy in biliary fibrosis. (Hepatology 2018;67:247-259).
Authors: Joel D Leverson; Darren C Phillips; Michael J Mitten; Erwin R Boghaert; Dolores Diaz; Stephen K Tahir; Lisa D Belmont; Paul Nimmer; Yu Xiao; Xiaoju Max Ma; Kym N Lowes; Peter Kovar; Jun Chen; Sha Jin; Morey Smith; John Xue; Haichao Zhang; Anatol Oleksijew; Terrance J Magoc; Kedar S Vaidya; Daniel H Albert; Jacqueline M Tarrant; Nghi La; Le Wang; Zhi-Fu Tao; Michael D Wendt; Deepak Sampath; Saul H Rosenberg; Chris Tse; David C S Huang; Wayne J Fairbrother; Steven W Elmore; Andrew J Souers Journal: Sci Transl Med Date: 2015-03-18 Impact factor: 17.956
Authors: James H Tabibian; Steven P O'Hara; Patrick L Splinter; Christy E Trussoni; Nicholas F LaRusso Journal: Hepatology Date: 2014-04-25 Impact factor: 17.425
Authors: Joachim C Mertens; Christian D Fingas; John D Christensen; Rory L Smoot; Steven F Bronk; Nathan W Werneburg; Michael P Gustafson; Allan B Dietz; Lewis R Roberts; Alphonse E Sirica; Gregory J Gores Journal: Cancer Res Date: 2012-12-05 Impact factor: 12.701
Authors: Thanh-Trang Vo; Jeremy Ryan; Ruben Carrasco; Donna Neuberg; Derrick J Rossi; Richard M Stone; Daniel J Deangelo; Mark G Frattini; Anthony Letai Journal: Cell Date: 2012-10-12 Impact factor: 41.582
Authors: James H Tabibian; Christy E Trussoni; Steven P O'Hara; Patrick L Splinter; Julie K Heimbach; Nicholas F LaRusso Journal: Lab Invest Date: 2014-07-21 Impact factor: 5.662
Authors: Mikolaj Ogrodnik; Yi Zhu; Larissa G P Langhi; Tamar Tchkonia; Patrick Krüger; Edward Fielder; Stella Victorelli; Rifqha A Ruswhandi; Nino Giorgadze; Tamar Pirtskhalava; Oleg Podgorni; Grigori Enikolopov; Kurt O Johnson; Ming Xu; Christine Inman; Allyson K Palmer; Marissa Schafer; Moritz Weigl; Yuji Ikeno; Terry C Burns; João F Passos; Thomas von Zglinicki; James L Kirkland; Diana Jurk Journal: Cell Metab Date: 2019-01-03 Impact factor: 27.287
Authors: Robert J Pignolo; João F Passos; Sundeep Khosla; Tamara Tchkonia; James L Kirkland Journal: Trends Mol Med Date: 2020-04-17 Impact factor: 11.951